Semaglutide
GLP-1 receptor agonist (Ozempic, Wegovy)
A GLP-1 receptor agonist with large-scale randomised cardiovascular and metabolic outcome trials. Unlike almost everything else in this library, it is an approved prescription medicine and research-grade supply is not a substitute for it.
- Category
- Fat Loss & Metabolic
- Half-life
- Approximately 7 days
- Cycle length
- Continuous, under medical supervision
- Level
- advanced
Overview
Semaglutide is a long-acting GLP-1 receptor agonist. It is genuinely in a different category from the rest of this site: it has been through large randomised controlled trials with cardiovascular, renal and metabolic endpoints, and it is approved as a medicine in most countries. It is included here because it dominates conversations in metabolic biohacking, and because the gap between the regulated product and grey-market research powder is a safety issue readers need stated plainly.
How it works
Semaglutide mimics glucagon-like peptide-1, a gut hormone released after eating. It increases glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying and acts on hypothalamic appetite centres to reduce hunger. Weekly dosing is possible because the molecule has been modified to resist DPP-4 degradation and to bind albumin.
Reported benefits
- Substantial and well-documented weight reduction
- Improved glycaemic control in type 2 diabetes
- Demonstrated cardiovascular risk reduction in outcome trials
- Reduced appetite and food noise
Reported benefits describe what the published literature and user reports suggest — not a promise of outcome for any individual.
Dosing reference
Prescription protocols escalate slowly: typically 0.25 mg weekly for four weeks, then 0.5 mg, then further steps to 1 mg or 2 mg weekly depending on response and tolerance. Slow escalation is not optional — it is how gastrointestinal side effects are managed.
Research-grade semaglutide is sold as a lyophilised powder requiring reconstitution, which introduces sterility and dosing-accuracy risks that the approved pen devices are specifically designed to eliminate. Titration schedules from clinical practice do not transfer cleanly to an unregulated powder.
Prescribed titration: 0.25 mg weekly for four weeks, then 0.5 mg, then 1 mg and 2 mg (up to 2.4 mg for obesity). Community reports broadly follow that schedule. The community-specific problem is unverified vials: users describe both under-dosing and accidentally taking far more than intended from mislabelled product.
These figures are what people report using in public communities. They have not been studied, verified or checked against certificates of analysis, and they are not a recommendation, a prescription or a target to aim for.
Where the reported amounts come from
Amounts are reproduced for education only. Doses from trials cannot be assumed to suit anyone else, and community-reported amounts are frequently wrong. Self-administering unapproved compounds carries serious risk.
The research picture
This is the best-evidenced compound in this library by an enormous margin. The STEP programme showed double-digit percentage body-weight reductions over 68 weeks in people without diabetes. SELECT showed a reduction in major cardiovascular events in people with overweight or obesity and existing cardiovascular disease. Cardiovascular and renal outcome trials have followed. The honest framing: the medicine works, and the practical question for a reader is almost always about access and supervision, not about whether the mechanism holds.
Preclinical & non-clinical data
A GLP-1 receptor agonist whose mechanism is thoroughly characterised, with large human trial data covered in the research section. Animal studies also show effects on inflammation and reward pathways that human data has not confirmed.
Non-clinical data comes from cells and animals unless stated otherwise. It answers whether a compound is worth studying in people — not whether it is safe or effective in them.
What users report
The largest public reporting base of any compound here, built over years of patient communities. What they describe, over and over: appetite disappearing within days, nausea and reflux in the first weeks of each dose increase, constipation, fatigue on titration days, and taste changes. Equally prominent are reports of weight returning after stopping and of people buying research vials and finding wildly inconsistent potency between weeks — a specific, repeated warning inside these communities. A minority describe mood changes that they credit to the drug rather than to the weight loss itself.
Where these reports come from
These are unverified personal accounts collected from public sources. They are not evidence of effectiveness or safety, they have not been independently checked, and they are not a recommendation to use anything described.
Possible side effects
- Nausea, most commonly during dose escalation
- Vomiting and diarrhoea
- Constipation
- Abdominal pain
- Gallbladder disease
- Pancreatitis (rare)
- Muscle mass loss alongside fat loss
Safety notes
Contraindicated with a personal or family history of medullary thyroid carcinoma or MEN2. Not for use in pregnancy — and because it slows gastric emptying, it needs to be stopped well before surgery. Serious interactions exist with insulin and sulfonylureas. This is a prescription medicine: obtaining it as research powder and self-dosing removes the oversight that the trials were built around, and dose-conversion errors from pen units to reconstituted powder are the single most common serious mistake in this space.
Stacking
Not a compound to stack informally. Clinically it is combined with structured resistance training and adequate protein specifically to preserve lean mass during rapid fat loss.
Related compounds
Retatrutide
LY3437943 — triple GLP-1 / GIP / glucagon receptor agonist
Fat Loss & Metabolic
The triple agonist that produced the largest weight reductions yet reported in a randomised obesity trial.
Cagrilintide
Long-acting amylin analogue — studied in combination with semaglutide
Fat Loss & Metabolic
An amylin analogue built to sit alongside a GLP-1 and push appetite suppression further.
AOD-9604
hGH fragment 176–191
Fat Loss & Metabolic
A fragment of growth hormone sold for fat loss, with trial results far more modest than the marketing.